Moyamoya disease: A review of histopathology, biochemistry, and genetics

Neurosurgical Focus

Volumn 30, Issue 6, 2011, Pages

  Weinberg, David G ^a   Arnaout, Omar M ^a   Rahme, Rudy J ^a   Aoun, Salah G ^a   Batjer, H Hunt ^a   Bendok, Bernard R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biochemistry; Genetics; Histopathology; Moyamoya disease

Indexed keywords

ANGIOGENIC PROTEIN; SIGNAL PEPTIDE;

BRAIN ARTERY; BRAIN CIRCULUS ARTERIOSUS; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MOYAMOYA DISEASE; MUTATION; PATHOLOGY; REVIEW;

ANGIOGENIC PROTEINS; CEREBRAL ARTERIES; CIRCLE OF WILLIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOYAMOYA DISEASE; MUTATION;

EID: 79958781143     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2011.3.FOCUS1151     Document Type: Article

References (43)

1. Achrol AS, Guzman R, Lee M, Steinberg GK: Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus 26(4):E4, 2009
2. Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S: Prothrombotic disorders in children with moyamoya syndrome. Stroke 32:1786-1792, 2001
3. Burke GM, Burke AM, Sherma AK, Hurley MC, Batjer HH, Bendok BR: Moyamoya disease: a summary. Neurosurg Focus 26(4):E11, 2009
4. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705, 1985
5. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T: Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 72:476-480, 2009
6. Fukui M: Current state of study on moyamoya disease in Japan. Surg Neurol 47:138-143, 1997
7. Fukui M, Kono S, Sueishi K, Ikezaki K: Moyamoya disease. Neuropathology 20 (Suppl):S61-S64, 2000
8. Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, Christofori G: Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 62:603-608, 2002
9. Garg AK, Suri A, Sharma BS: Ten-year experience of 44 patients with moyamoya disease from a single institution. J Clin Neurosci 17:460-463, 2010
10. Gohda E: [Function and regulation of production of hepatocyte growth factor (HGF).] Nippon Yakurigaku Zasshi 119:287-294, 2002 (Jpn)
11. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, et al: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1:74-79, 1995
12. Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, et al: Role of transforming growth factor-®1 in the pathogenesis of moyamoya disease. J Neurosurg 89:623-629, 1998
13. Horn P, Bueltmann E, Buch CV, Schmiedek P: Arterio-embolic ischemic stroke in children with moyamoya disease. Childs Nerv Syst 21:104-107, 2005
14. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Caillat-Zucman S, Beaugerie L, Dupas JL, et al: Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease. G.E.T.A.I.D. Am J Med Genet 52:207-213, 1994
15. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T: Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64:533-537, 1999
16. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M: Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15:179-182, 2000
17. Karzmark P, Zeifert PD, Tan S, Dorfman LJ, Bell-Stephens TE, Steinberg GK: Effect of moyamoya disease on neuropsychological functioning in adults. Neurosurgery 62:1048-1052, 2008
18. Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, et al: Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 34:2835-2841, 2003
19. Kuroda S, Houkin K: Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056-1066, 2008
20. Ma MS, Zou LP, Ding YX, Jin H: [Concentrations of granulocyte colony-stimulating factor in children with moyamoya disease.] Zhongguo Dang Dai Er Ke Za Zhi 12:117-119, 2010 (Chinese)
21. Malek AM, Connors S, Robertson RL, Folkman J, Scott RM: Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 27:182-189, 1997
22. Masuda J, Ogata J, Yutani C: Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24:1960-1967, 1993
23. Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, et al: Epidemiological and clinical features of Moyamoya disease in Nanjing, China. Clin Neurol Neurosurg 112:199-203, 2010
24. Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, et al: Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 70:2357-2363, 2008
25. Nanba R, Kuroda S, Ishikawa T, Houkin K, Iwasaki Y: In creased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35:2837-2842, 2004
26. Presta M, Statuto M, Isacchi A, Caccia P, Pozzi A, Gualandris A, et al: Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region. Biochem Biophys Res Commun 185:1098-1107, 1992
27. Sakamoto S, Kiura Y, Yamasaki F, Shibukawa M, Ohba S, Shrestha P, et al: Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease. Neurosurg Rev 31:77-81, 2008
28. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al: A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49:278-281, 2004
29. Shinkaruk S, Bayle M, Laïn G, Déléris G: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3:95-117, 2003
30. Soriano SG, Cowan DB, Proctor MR, Scott RM: Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 50:544-549, 2002
31. Suzuki J, Takaku A: Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288-299, 1969
32. Takagi Y, Kikuta K, Nozaki K, Hashimoto N: Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo) 47:1-4, 2007
33. Takahashi A, Sawamura Y, Houkin K, Kamiyama H, Abe H: The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 160:214-216, 1993
34. Takekawa Y, Umezawa T, Ueno Y, Sawada T, Kobayashi M: Pathological and immunohistochemical findings of an autopsy case of adult moyamoya disease. Neuropathology 24: 236-242, 2004
35. Uchino K, Johnston SC, Becker KJ, Tirschwell DL: Moyamoya disease in Washington State and California. Neurology 65:956-958, 2005
36. van Setten GB: Basic fibroblast growth factor in human saliva: detection and physiological implications. Laryngoscope 105:610-612, 1995
37. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al: Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 99 (Suppl 2):S1-S5, 1997
38. Yamada H, Deguchi K, Tanigawara T, Takenaka K, Nishimura Y, Shinoda J, et al: The relationship between moyamoya disease and bacterial infection. Clin Neurol Neurosurg 99 (Suppl 2):S221-S224, 1997
39. Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, et al: Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28:1733-1738, 1997
40. Yamashita M, Oka K, Tanaka K: Cervico-cephalic arterial thrombi and thromboemboli in moyamoya disease-possible correlation with progressive intimal thickening in the intracranial major arteries. Stroke 15:264-270, 1984
41. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al: Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930-935, 2000
42. Yoshimoto T, Houkin K, Takahashi A, Abe H: Angiogenic factors in moyamoya disease. Stroke 27:2160-2165, 1996
43. Zsebo KM, Cohen AM, Murdock DC, Boone TC, Inoue H, Chazin VR, et al: Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 172:175-184, 1986